Neuropathy Impairment Trials Need 4-Year Duration, Committee Suggests
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Studies assessing drugs for impairment in diabetic neuropathy should be at least four years in duration, consultants to the May 16 FDA Advisory Committee on Anesthetic and Life Support Drugs recommended.